Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. PMID: 35074072.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCTClinical Trials
Bacterial protease activity as a biomarker to assess the risk of non-healing in chronic wounds: Results from a multicentre randomised controlled clinical trial. Wound Repair Regen. 2021 09; 29(5):752-758.
Serena TE, Bayliff SW, Brosnan PJ, DiMarco DT, Doner BA, Guthrie DA, Patel KD, Sabo MJ, Samies JH, Carter MJ. PMID: 34057796.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCells